- Home
- NBP vs DTIL Comparison
NBP vs DTIL Comparison
Compare NBP & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBP | DTIL |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.9M | 214.7M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NBP | DTIL |
|---|---|---|
| Price | $1.70 | $7.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 253.2K | 243.3K |
| Earning Date | 04-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $3.53 |
| 52 Week High | $5.19 | $9.62 |
Technical Indicators
Market Signals| Indicator | NBP | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 40.71 |
| Support Level | $1.67 | $7.18 |
| Resistance Level | $1.98 | $7.92 |
| Average True Range (ATR) | 0.10 | 0.40 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 2.94 | 5.61 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).